ArticleBMC bioinformatics2025
MFCADTI: improving drug-target interaction prediction by integrating multiple feature through cross attention mechanism.
Article in BMC bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- DMAPLM: A multimodal pretrained framework for computational drug repositioning.PLoS computational biology · 2026Article
- KG-DFI: A Prediction of Drug-Food Interactions Based on Knowledge Graph Embedding.Computational and structural biotechnology journal · 2026Article
- QKDTI A quantum kernel based machine learning model for drug target interaction prediction.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Accurately identifying potential drug-target interactions (DTIs) is a critical step in drug discovery. Multiple heterogeneous biological data provide abundant features for DTI prediction. Many computational methods have been proposed based on these data. However, most of these methods either extract features from sequences or from networks, utilizing only one aspect of the characteristics of drugs and targets, neglecting the complementary information between these two types of features. In fact, integrating different types of features will provide more valuable information for DTI prediction. In this article, we propose a novel method to improve the predictive capability for DTIs, named MFCADTI, by integrating multi-source feature through cross-attention mechanisms. The method extracts network topological features from the heterogeneous network and attribute features from sequences of drugs and targets. Considering the complementarity and heterogeneity between network and attribute features, cross-attention mechanisms are used to integrate the network and attribute features of drugs and targets. To capture the correlations between drugs and targets, cross-attention is used to learn the interaction features of each drug-target pair. We evaluate MFCADTI on two datasets and experimental results demonstrate a significant improvement in the performance of MFCADTI compared to state-of-the-art methods. Finally, case studies illustrate that MFCADTI is an effective DTI prediction way that provides valuable guidance for drug development. The data and source code used in this study are available at: https://github.com/Dejavun/MFCADTI .
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.